Skip to main content
OpenTrials

Clinical trial condition

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Explore clinical trials studying Post-essential Thrombocythemia Myelofibrosis (Post-ET MF). Study availability and eligibility vary by location and protocol.

4 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) trial results

Recruiting

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Novartis Investigative Site Kamogawa, Chiba, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Novartis Investigative Site Kamakura, Kanagawa, Japan
  • Novartis Investigative Site Kurashiki, Okayama-ken, Japan
View Trial Details
Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Atlanta, Georgia, United States
  • Kansas City, Kansas, United States
View all 48 locations
View Trial Details
Active, Not Recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +6 more
Locations
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Orange, California, United States
  • GSK Investigational Site Stanford, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
View all 112 locations
View Trial Details

Related conditions